Inhibitors of acyl-CoA:cholesterol O-acyltransferase.: 2.: Identification and structure-activity relationships of a novel series of N-alkyl-N-(heteroaryl-substituted benzyl)-N′-arylureas

被引:72
作者
Tanaka, A
Terasawa, T
Hagihara, H
Sakuma, Y
Ishibe, N
Sawada, M
Takasugi, H
Tanaka, H
机构
[1] Fujisawa Pharmaceut Co Ltd, Med Chem Res Labs, Yodogawa Ku, Osaka 532, Japan
[2] Fujisawa Pharmaceut Co Ltd, Med Biol Res Labs, Yodogawa Ku, Osaka 532, Japan
[3] Fujisawa Pharmaceut Co Ltd, New Drug Res Labs, Yodogawa Ku, Osaka 532, Japan
[4] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 30026, Japan
关键词
D O I
10.1021/jm9800853
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylurea and related derivatives represented by 2 and 3 have been prepared and evaluated for their ability to inhibit acyl-CoA: cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Among these novel compounds, the type 3 series was superior. A pyrazol-3-yl group on the N-benzyl group of this trisubstituted urea (i.e. 3, Ar-1 = pyrazol-3-yl) was identified as a heteroaromatic ring providing a good profile of biological activity. As a result of optimization of the combination with the N-alkyl group (R) and N-aryl group (Ar-3), compound 3aq (FR186054) was identified as a new, orally efficacious ACAT inhibitor, which exhibited potent in vitro ACAT inhibitory activity (rabbit intestinal microsomes IC50 = 99 nM) and excellent hypocholesterolemic effects in cholesterol-fed rats, irrespective of administration mode (ED50 = 0.046 mg/kg dosed via the diet, ED50 = 0.44 mg/kg administered by gavage in PEG400 vehicle). Moreover, a toxicological study revealed compound 3aq to be nontoxic to the adrenal glands of dogs when tested at a single dose of 10 mg/kg po.
引用
收藏
页码:2390 / 2410
页数:21
相关论文
共 56 条
[1]  
BADIMON JJ, 1993, CIRCULATION, V87, P3
[2]   LIPOPROTEIN METABOLISM IN THE MACROPHAGE - IMPLICATIONS FOR CHOLESTEROL DEPOSITION IN ATHEROSCLEROSIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1983, 52 :223-261
[3]   DEMONSTRATION OF A DIRECT EFFECT ON HEPATIC ACYL COA-CHOLESTEROL ACYL TRANSFERASE (ACAT) ACTIVITY BY AN ORALLY-ADMINISTERED ENZYME-INHIBITOR IN THE HAMSTER [J].
BURRIER, RE ;
DEREN, S ;
MCGREGOR, DG ;
HOOS, LM ;
SMITH, AA ;
DAVIS, HR .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (09) :1545-1551
[4]   STUDY OF PROTON NUCLEAR MAGNETIC-RESONANCE SPECTRA OF ARYL AND MONOSUBSTITUTED AND DISUBSTITUTED N-METHYLAZOLES [J].
BUTLER, RN .
CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE, 1973, 51 (14) :2315-2322
[5]  
CARLSEN HJ, 1994, J HETEROCYCLIC CHEM, V31, P805
[6]  
CARR TP, 1990, ARTERIOSCLEROSIS, V10, pA823
[7]   HEPATIC ACAT ACTIVITY IN AFRICAN-GREEN MONKEYS IS HIGHLY CORRELATED TO PLASMA LDL CHOLESTERYL ESTER ENRICHMENT AND CORONARY-ARTERY ATHEROSCLEROSIS [J].
CARR, TP ;
PARKS, JS ;
RUDEL, LL .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (11) :1274-1283
[8]   Acyl-coenzyme A: Cholesterol acyltransferase [J].
Chang, TY ;
Chang, CCY ;
Cheng, D .
ANNUAL REVIEW OF BIOCHEMISTRY, 1997, 66 :613-638
[9]   POTENTIAL ANTIATHEROSCLEROTIC AGENTS .5. AN ACYL-COA - CHOLESTEROL O-ACYLTRANSFERASE INHIBITOR WITH HYPOCHOLESTEROLEMIC ACTIVITY [J].
DEVRIES, VG ;
SCHAFFER, SA ;
LARGIS, EE ;
DUTIA, MD ;
WANG, CH ;
BLOOM, JD ;
KATOCS, AS .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (07) :1131-1133
[10]   POTENTIAL ANTIATHEROSCLEROTIC AGENTS .6. HYPOCHOLESTEROLEMIC TRISUBSTITUTED UREA ANALOGS [J].
DEVRIES, VG ;
BLOOM, JD ;
DUTIA, MD ;
KATOCS, AS ;
LARGIS, EE .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (10) :2318-2325